Form 4: Adicet Bio CFO Acquires Stock Options
SEC Form 4 Filing
Brian Nicholas Harvey, CFO of Adicet Bio, Inc., reports the acquisition of stock options.
Summary
- Brian Nicholas Harvey, the Chief Financial Officer of Adicet Bio, Inc., filed a Form 4 with the SEC.
- The filing reports a transaction that occurred on January 31, 2025.
- Harvey acquired 324,040 stock options with an exercise price of $0.885.
- These options vest monthly over 48 months from the grant date, contingent on continued service with Adicet Bio.
- Following the transaction, Harvey directly owns 324,040 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting the acquisition of stock options by a company executive. It doesn't inherently convey strong positive or negative sentiment.
Positives
- The acquisition of stock options by the CFO could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the transactions of company executives and directors, which can be informative for investors.
Stakeholder Impact
- The acquisition of stock options by the CFO could potentially impact shareholder confidence, depending on how investors interpret the transaction.
Key Dates
| Date | Description |
|---|---|
| 01/31/2025 | Date of the stock option transaction. |
| 01/30/2035 | Expiration date of the stock options. |
| 02/04/2025 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.